Stéphane Ramin-Mangata, Aurélie Thedrez, Brice Nativel, Nicolas Diotel, Valentin Blanchard, Matthieu Wargny, Audrey Aguesse, Stéphanie Billon-Crossouard, Cécile Vindis, Cédric Le May, Philippe Hulin, Mathieu Armanet, Valery Gmyr, François Pattou, Mikaël Croyal, Olivier Meilhac, Estelle Nobécourt, Bertrand Cariou, Gilles Lambert
BACKGROUND AND AIMS: Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) is an endogenous inhibitor of the LDL receptor (LDLR). Mendelian randomization studies suggest that PCSK9 deficiency increases diabetes risk, but the underlying mechanisms remain unknown. The aim of our study was to investigate whether PCSK9 or its inhibition may modulate beta cell function. METHODS: We assessed PCSK9 and insulin colocalization in human pancreatic sections by epifluorescent and confocal microscopy...
April 20, 2021: Atherosclerosis